

Developmental dosing with a MEK inhibitor (PD0325901) rescues myopathic features of the muscle-specific but not limb-specific *Nf1* knockout mouse

Matthew A Summers^{1,2}, Emily R Vasiljevski^{1,2}, Kathy Mikulec¹, Lauren Peacock¹, David G Little^{1,2}, Aaron Schindeler^{1,2§}

1. Orthopaedic Research & Biotechnology, The Children's Hospital at Westmead, Westmead, NSW, Australia.
2. Discipline of Paediatrics & Child Health, Faculty of Medicine, University of Sydney, Camperdown, NSW, Australia

§ Corresponding author

Mailing address:

Orthopaedic Research & Biotechnology, Research Building
The Children's Hospital at Westmead
Locked Bag 4001
Westmead, NSW 2145, Australia
Phone: +61-2-98451451
Fax: +61-2-98453078
Email: aaron.schindeler@sydney.edu.au

Conflicts of interest

Authors have no conflicts of interest to declare.

Keywords: Neurofibromatosis type 1 (NF1), muscle weakness, myopathy, MEK inhibitor

Download English Version:

<https://daneshyari.com/en/article/8343069>

Download Persian Version:

<https://daneshyari.com/article/8343069>

[Daneshyari.com](https://daneshyari.com)